Abacus Global Management 3Q26 Earnings Call - ABACUS GLOBAL MANAGEMENT INC

Financial Performance:

• Third-quarter revenue reached $76.9 million, a 22% year-over-year increase, driven by Life Solutions revenue of $71.3 million (+32% YoY) and Technology Services revenue of $0.6 million (+155% YoY).
• Adjusted net income was $29.4 million, exceeding the guidance range and representing a 24% YoY growth, resulting in adjusted EPS of $0.29.
• Adjusted EBITDA totaled $42.3 million with a margin of 55%, up 12% YoY; cash conversion was strong with $1.46 of operating cash flow generated for every dollar of adjusted EBITDA year-to-date.
• Operating expenses rose 32% to $43.4 million, primarily due to $5.2 million in higher legal/professional fees and $1.8 million in hiring costs from acquisitions.
• Cash reserves were $104 million at quarter-end; policy assets stood at $370 million with long-term debt (excluding non-recourse) at $366 million.
• Return on equity (ROE) increased to 26%, up 440 basis points YoY; average realized gain on policy sales was approximately 24%, exceeding the 20% long-term target.

Guidance and Future Outlook:

• Raised full-year 2026 adjusted net income guidance to $104.5–$106.5 million (previously $100–$106 million), representing up to 24% growth over 2025.
• Raised full-year 2026 adjusted EPS guidance to $1.05–$1.07 (previously $1.00–$1.05).
• Q4 2026 guidance set at adjusted net income of $28–$30 million (adjusted EPS $0.28–$0.30), indicating up to 30% YoY growth.
• Targeting 2–3 securitizations annually, with the next planned for Q1 2027, aiming for consistent capital deployment of $130–$160 million per quarter.
• Projecting a revenue mix shift by 2030, with a long-term goal of 70% fee-related revenue, currently at 11%, driven by fund inflows and securitization residual income.

Business Segments and Product Lines:

• LifeArk: Launched as a consumer-facing platform utilizing proprietary longevity data; generated 357 inquiries in early days representing over $500 million in investable assets, with 91% of inquirers aged 50+.
• Capital Inflows: Longevity fund inflows totaled $997 million through Q3 2026, compared to $604 million for all of 2025; Q3 alone saw $452.4 million in inflows (6x prior year rate).
• Securitization: Completed a $400+ million securitization (8x the inaugural size), oversubscribed and placed primarily with insurance companies; includes a 15% residual interest and 50–100 bps annual servicing fees.
• Strategic Partnerships: Live partnerships with Retirable (serving RIAs) and Manning & Napier (enrolling clients into LifeArk and distributing funds) to drive lead generation and AUM growth.
• ABX Longevity Growth and Income Fund: Interval fund product gaining traction with RIAs and pension funds, expected to see significant flows in Q1 2027.

Market and Competitive Landscape:

• Market validation achieved through investment-grade rating of securitization notes by major insurance companies, confirming fair value of assets amidst private asset valuation debates.
• LifeArk dominates branded search, holding the #1 Google position for its name with a five-fold increase in search clicks post-announcement.
• The business leverages a "flywheel" effect where capital recycling via securitization and funds accelerates origination volume and turnover.
• Asset class (longevity/life settlement) noted for low correlation to broader market volatility, potentially attracting capital during periods of economic uncertainty.

Risks and Challenges:

• Regulatory environment: Potential Democratic priorities regarding estate tax adjustments could influence policy acquisition volumes; however, current regulatory path is viewed as favorable.
• Interest rate sensitivity: Management models conservatively targeting a 20% realized gain to maintain flexibility against short-term interest rate movements.
• Inventory management: Balancing capital deployment with securitization timing to avoid over-stocking or under-stocking policy inventory.
• Execution risk: Scaling the LifeArk consumer platform and maintaining high inquiry-to-conversion rates in a new market segment.

Management Commentary and Tone:

• Tone is highly confident and momentum-focused, describing the quarter as "momentous" with strong strategic progress and market validation.
• Management emphasized the "cash conversion" of earnings as a primary proof point for asset valuation.
• Emphasized a "balance sheet light" approach using securitization and funds to recycle capital efficiently while retaining servicing fees and residual interests.
• Reiterated commitment to capital allocation discipline, linking share repurchases to ROE and stock upside potential.

Analyst Questions and Answers:

• Political Risk: Confirmed that potential estate tax reversals could increase policy sales volume, providing a long-term tailwind.
• Fund Distribution: ABX interval fund is progressing well with RIAs and institutional investors, bypassing platform time-lock requirements via direct partnerships.
• Fee Mix: A temporary dip in AUM fees was attributed to closed-end fund maturations and ETF flows; expected to reverse in Q4/Q1 driven by securitization and fund growth.
• Securitization Economics: Not breaking out specific Q3 one-time gains from securitization, but highlighted increased capital deployment velocity and 3x annualized turnover as key benefits.
• Capital Constraints: Origination volume growth is tied to securitization inventory matching and duration; 100% YoY growth in capital deployed deemed unrealistic; targeting consistent 20–24% growth.
• Debt Strategy: Senior notes callable in Feb 2027 will likely be refinanced rather than cashed; comfortable with current debt multiples and potential for strategic refinancing.

Other Key Points:

• Capital Return: Board authorized a $100 million share repurchase program (running through May 2028); Q3 repurchased $1.7 million at $8.13 avg price.
• Dividend: Approved a 10% increase in the annual dividend to $0.22 per share, with an ex-dividend date of December 1, 2026.
• Operational Efficiency: Reviewed 101,000+ qualified policies year-to-date; average hold period for sold policies dropped to 62 days from 212 days for retained policies due to capital recycling.
• Data Asset: Highlighted 20 years of proprietary longevity and HIPAA-compliant medical data as a core competitive moat transitioning from institutional to consumer use via LifeArk.